FDA panel on peptides will include experts who promote the unproven chemicals favored by RFK Jr.

FDA Peptide Panel Includes Industry Advocates with Ties to RFK Jr’s Movement

FDA panel on peptides will include – The Food and Drug Administration (FDA) is set to convene a pivotal meeting in July to reassess the safety and efficacy of several peptide-based therapies. This two-day session will feature a unique lineup of participants, many of whom are not only practitioners but also active promoters of unproven peptide compounds. The shift in composition reflects a broader effort by Health Secretary Robert F. Kennedy Jr. to align FDA policies with his “Make America Healthy Again” initiative, which has gained traction among wellness advocates and alternative medicine proponents.

Redefining Expertise: A New Approach to Regulation

Unlike previous FDA panels, which were dominated by academic researchers and university-based experts, this new group includes a significant number of healthcare professionals directly involved in the peptide industry. These individuals, such as doctors and pharmacists, have financial interests in the production, distribution, or marketing of peptide products. Their participation raises questions about potential conflicts of interest, as they may prioritize industry-backed claims over rigorous scientific scrutiny.

Peptides—short chains of amino acids—have emerged as a popular tool in wellness trends, often marketed as miracle solutions for muscle growth, injury recovery, and anti-aging. While some are FDA-approved, many others are sold as unregulated research chemicals, allowing manufacturers to bypass traditional regulatory hurdles. This has created a kind of regulatory “Wild West,” where peptides are widely available through online retailers and clinics without extensive human trials to back their benefits.

The Influence of the Make America Healthy Again Movement

Robert F. Kennedy Jr.’s advocacy for peptides is part of a larger movement to challenge conventional medical standards. His supporters argue that these substances offer natural, accessible alternatives to pharmaceutical treatments, especially for conditions like chronic pain or fatigue. However, critics within the pharmaceutical industry view peptides as a growing threat, citing their lack of regulatory oversight and the potential for misuse.

Some of the most prominent backers of the movement are also key figures in the peptide market. These entities sell products that claim to enhance physical performance, promote longevity, or restore youth. Despite the popularity of such offerings, scientific evidence supporting these assertions remains limited. The FDA has long warned about the risks associated with peptides like BPC-157 and TB-500, which are often used as doping agents in international sports. These substances, though widely available, have not undergone comprehensive human studies to confirm their safety or effectiveness.

Industry Affiliations and Political Connections

Among the panelists is Bobby Harshbarger, a Tennessee state senator with deep ties to the peptide industry. Harshbarger operates a family-owned pharmacy, Premiere Pharmacy, which specializes in compounded medications for weight loss, vitality, and chronic conditions. His mother, Rep. Diana Harshbarger, also serves as a pharmacist in Congress, adding another layer of political influence to the discussion. Last year, she advocated for relaxed FDA restrictions on several peptides, a stance that aligns with Robert F. Kennedy Jr.’s vision for healthcare reform.

Harshbarger’s connections extend beyond his family business. His wife, Robert Harshbarger Jr., was pardoned by President Donald Trump in 2020 after pleading guilty to substituting an unapproved Chinese drug for a standard treatment used by dialysis patients. The former pharmacist served a four-year prison sentence, which underscores the regulatory risks associated with the peptide industry. Despite this, the Harshbargers continue to promote the use of compounded peptides, leveraging their political clout to shape public perception.

Panel Members and Their Roles

Dr. Haleem Mohammed, a Florida-based practitioner, is another notable panelist. His clinics, part of a national chain called Gameday Men’s Health, offer a range of injectable therapies, including peptides, vitamins, and testosterone. The company’s website states that its compounded medications are not FDA-approved and that the agency does not verify their safety. This disclaimer highlights the growing disconnect between the industry and regulatory authorities.

Dr. Gabriel Alizaidy, who charges $500 for “peptide and hormone” consultations, has built a significant following on social media platforms like Instagram and TikTok. His advice often includes recommendations on where to safely obtain various peptides, even as he promotes substances such as BPC-157 and GHK-Cu. Alizaidy’s website clarifies that his consultations are “educational in nature” and do not qualify as medical treatment, a statement that has sparked debate about the responsibility of influencers in healthcare decisions.

The Debate Over Regulation and Evidence

The FDA’s decision to include industry-linked experts in its review process has drawn mixed reactions. While some argue that diverse perspectives are necessary for policy development, others worry about the integrity of the evaluation. Peptide sellers frequently rely on the “research use only” label to avoid FDA oversight, a tactic that allows them to market products without proving their therapeutic benefits. This practice has led to a proliferation of untested therapies, often sold with promises that exceed current scientific understanding.

Compounding pharmacies, which play a central role in the peptide market, have been a focal point of FDA scrutiny. These pharmacies mix custom medications that are not mass-produced by traditional pharmaceutical companies. While they provide valuable services for patients with unique needs, they also face criticism for distributing unapproved drugs without adequate oversight. The FDA has previously voted against several peptide ingredients, citing their potential risks to public health. This new panel, however, may be more inclined to support their use, given the industry’s growing influence.

What’s at Stake for the FDA?

The upcoming meeting marks a turning point in the FDA’s approach to peptide regulation. By bringing in panelists with direct ties to the industry, the agency is signaling a willingness to balance innovation with caution. Yet, the inclusion of these experts may also signal a shift toward policies that prioritize accessibility over safety, especially as peptides continue to attract attention from athletes, celebrities, and influencers eager to explore alternative health solutions.

As the FDA weighs its options, the debate over peptides will likely intensify. While some advocate for expanded access to these substances, others warn of the dangers posed by their unproven nature. The outcome of this meeting could have far-reaching implications for the future of peptide therapy, shaping how patients and practitioners view their role in the healthcare landscape. For now, the panel’s composition suggests that the agency is navigating a complex intersection of science, politics, and commerce, with the ultimate goal of redefining health standards in the United States.

“Compounded medications offered through our services are not FDA-approved, and the FDA does not verify their safety.” — Gameday Men’s Health website

“Each consultation is educational in nature and does not constitute medical care, diagnosis, or treatment.” — Dr. Gabriel Alizaidy’s website

With the panel’s final decisions expected in July, the spotlight will remain on the FDA as it seeks to reconcile the demands of the peptide industry with its mandate to protect public health. Whether this meeting will lead to greater support for unproven therapies or stricter regulations remains to be seen, but one thing is clear: the voices shaping this debate are no longer limited to scientists alone.